서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 14 of 14

Issue DateTitle / Author(s) / CitationFileAltmetrics
2015-03
Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL)
DOI
2017-04
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
view fileDOI
2017-11
Diagnosis of secondary peripheral neurolymphomatosis: A multi-center experience
DOI
2018-03
Efficacy of pemetrexed-based chemotherapy in comparison to non-pemetrexed-based chemotherapy in advanced, ALK plus non-small cell lung cancer
view fileDOI
2018-03
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
DOI
2018-08
Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity
DOI
2019-01
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
view fileDOI
2019-10
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
DOI
2019-11
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer
view fileDOI
2020-07
Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors
DOI
2020-12
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
DOI
2021-01
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
DOI
2021-02
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
DOI
2021-08
A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
1